Mikhail Blagosklonny is an Invaluable Asset in the Medical World

Mikhail Blagosklonny is a prominent individual in the world of medicine due to his contributions. He is not only an oncologist, but a professor, scientist, author, and editor. Presently, he is working as the Oncology Professor at the Roswell Park Cancer Institute. Furthermore, at the same institute, Mr. Blagosklonny works in other departments including Hematology and Cell Stress Biology specializing in Protein kinases, signal induction, and phosphorylation among others. Mikhail believes that one day the world can be cancer free and with slow aging organisms. Read more on templeofthecave.com

Education and Work History

In the past, Mikhail was working as the Senior Scientist at Ordway Research Institute. Mr. Blagosklonny received his medical degree from the First Pavlov State Medical University based in St Petersburg. Additionally, he also has Ph.D. in Cardiology and Experimental Medicine from the same University. After graduating with a Ph.D., the New York Medical College hired Mikhail as the Associate Professor of Medicine, a position he held until when he moved to Ordway. Other areas that Mikhail researches on include cell cycle, anti-cancer treatments, tumor suppressors, molecular & cellular biology and apoptosis.

Aging Research

The scientist Mikhail Blagosklonny most recognized research included his work on reversing the aging process. According to the professor, he believes that Rapamycin, a commonly used drug for treating cancer has the required properties needed to slow down aging. Mikhail’s work on the role of TOTR in anti-aging and cancer treatment has augmented the doctor’s profile in the medical fraternity. Further research on the matter is still at large, and Rapamycin has also been proved to work on animals as well.

Oncotarget

Professor Blagosklonny is one of the co-founders and also editorial chief for the Oncotarget journal. Oncotarget is a free, peer-reviewed, online journal that hosts articles from several leading oncologists across the globe. Its primary aim is to enhance cancer treatment by documenting several cancer therapies. Oncotarget has been documented to have an impact factor of 5. The journal was established just six years ago; however, it currently prides of having the most recent up-to-date content in the medical industry. This is because it adds new content on a weekly basis. Moreover, the journal is free which means that any interested person can access it.

At first, Oncotarget was designed to focus on just oncology; however, due to its growing popularity among practitioners, it has expanded its scope. Currently, it hosts topics in several areas like Pharmacology, Immunology/Microbiology, Cardiology, Neuroscience, Cell Death, Endocrinology, Gerotarget/Aging, and Neuropathology. Because of the new scope of information, the medical journal will attract even more readers and benefactors. Read more about Mikhail at LinkedIn.com

Other Editorial Projects

Other than Oncotarget, Blagosklonny is also the chief editor of other medical journals including Aging and Cell Death & Differentiation. Moreover, he is an associate editor at Cancer Biology & Therapy and PLOS. Scientist Mikhail is also an author of over 300 articles, reviews, book chapters, and research papers published in his name. Blagosklonny work has been cited approximately over 25,000 times earning him an 83 h-index.

Leave a Reply

Your email address will not be published. Required fields are marked *